The 10 most recent market catalysts affecting $LGND, each scored for sentiment and estimated stock impact. Sourced from SEC EDGAR filings and financial news, analysed automatically as they are published.
Sep 25, 2026
Corporate Catalyst
Neutral
Impact 65
Barclays Initiates Coverage On Ligand Pharmaceuticals with Overweight Rating, Announces Price Target of $345
Barclays analyst Glen Santangelo initiated coverage on Ligand Pharmaceuticals (LGND) with an 'Overweight' rating and a price target of $345. This is a positive development for LGND…
Sep 24, 2026
Market Technicals
Neutral
Impact 55
HC Wainwright & Co. Reiterates Buy on Ligand Pharmaceuticals, Maintains $358 Price Target
HC Wainwright & Co. analyst Joseph Pantginis reiterated a 'Buy' rating and maintained a $358 price target for Ligand Pharmaceuticals. This action signals continued bullish sentimen…
Sep 23, 2026
Corporate Catalyst
Bullish
Impact 55
Citigroup Maintains Buy on Ligand Pharmaceuticals, Raises Price Target to $397
Citigroup analyst Yigal Nochomovitz maintained a 'Buy' rating on Ligand Pharmaceuticals and raised the price target from $390 to $397. This action signals continued confidence from…
Aug 14, 2026
Corporate Catalyst
Neutral
Impact 65
Leerink Partners Initiates Coverage On Ligand Pharmaceuticals with Outperform Rating, Announces Price Target of $330
Leerink Partners, through analyst David Risinger, has initiated coverage on Ligand Pharmaceuticals (LGND) with an 'Outperform' rating and a price target of $330. This event is sign…
Aug 7, 2026
Corporate Catalyst
Bullish
Impact 55
RBC Capital Maintains Outperform on Ligand Pharmaceuticals, Raises Price Target to $345
RBC Capital's analyst Douglas Miehm maintained an 'Outperform' rating for Ligand Pharmaceuticals and slightly increased the price target from $340 to $345. This action signals ongo…
Aug 6, 2026
Corporate Catalyst
Bullish
Impact 55
HC Wainwright & Co. Maintains Buy on Ligand Pharmaceuticals, Raises Price Target to $358
HC Wainwright & Co. analyst Joseph Pantginis maintained a 'Buy' rating on Ligand Pharmaceuticals and raised the price target from $289 to $358. This upward revision in the price ta…
Aug 6, 2026
Corporate Catalyst
Bullish
Impact 75
Ligand Pharmaceuticals Q2 Adj. EPS $2.37 Beats $1.84 Estimate, Sales $63.693M Beat $60.765M Estimate
This headline is a significant corporate catalyst for Ligand Pharmaceuticals. Beating both EPS and sales estimates by a considerable margin suggests strong underlying business fund…
Aug 3, 2026
Corporate Catalyst
Bullish
Impact 65
Oppenheimer Reiterates Outperform on Ligand Pharmaceuticals, Raises Price Target to $326
Oppenheimer analyst Leland Gershell reiterated an 'Outperform' rating for Ligand Pharmaceuticals and raised the price target from $285 to $326. This upgrade signals increased confi…
Jul 21, 2026
Corporate Catalyst
Neutral
Impact 65
Citigroup Reinstates Buy on Ligand Pharmaceuticals, Announces $387 Price Target
Citigroup's reinstatement of a 'Buy' rating and establishment of a $387 price target for Ligand Pharmaceuticals (LGND) is a positive development for the company. Analyst ratings an…
Jul 15, 2026
Corporate Catalyst
Bullish
Impact 65
RBC Capital Maintains Outperform on Ligand Pharmaceuticals, Raises Price Target to $340
RBC Capital analyst Douglas Miehm reiterated an Outperform rating for Ligand Pharmaceuticals and significantly raised the price target from $262 to $340. This analyst upgrade indic…
Not financial advice. AI-generated analysis for informational purposes only. Tradow AI LLC is not a registered investment adviser.